Skip to content

Savara SVRA Cash ratio

Cash ratio at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
0.9×+0.3×
Innoviva, Inc. logo
Innoviva, Inc.INVA
16.5×+15.1×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
+0.6×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
1.3×+0.6×
Theravance Biopharma logo
Theravance BiopharmaTBPH
9.1×+5.6×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
0.4×-0.2×

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Calculated from Savara’s reported figures.

Based on the most recent quarter.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's cash ratio?
Savara (SVRA) reported cash ratio of 2.5× in Q1 2026.
How has Savara's cash ratio changed year-over-year?
Savara's cash ratio increased by 51.9% year-over-year, from 1.6× to 2.5×.
What is the long-term trend for Savara's cash ratio?
Over 5 years (2020 to 2025), Savara's cash ratio has grown at a -10.3% compound annual growth rate (CAGR), from 2.8× to 1.6×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.